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Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli 
(UPEC) are a serious problem worldwide, especially for females. Previous research in 
our laboratory suggests that cranberry pectic oligosaccharides (cPOS) can reverse 
dormant phenotypes in UPEC and therefore could prove useful in the prevention of 
recurrent UTIs. This thesis focused on the purification and structure determination of 
purified pectic oligosaccharides from cranberry hull extract. The research helped 
established the structures of cPOS, provided high purity materials for biological testing, 
and enabled further studies on the effect of different degrees of polymerization (DP) in 
preventing dormant phenotypes in UPEC. More specifically, cPOS was determined to 
be comprised of galacturonic acid residues by applying chemical derivatization methods. 
Small quantities of terpene glycosides impurities in previously tested fractions were 
removed successfully by implementing a trituration method. The bioassay results of 
terpene glycosides-free cPOS confirmed the impurities were not responsible for the 
bioactivity of cPOS. Finally, a semi-preparative HPLC method using HILIC 
chromatography was established for the purification of cPOS components with variable 
DPs. A preliminary structure-activity relationship based on the variation of cPOS DPs 
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Urinary tract infections (UTIs) are one of the most prevalent infectious diseases 
worldwide, affecting people of all ages.1 It is estimated that 10.5 million UTI cases occur 
annually in United states.2 Although most UTI patients only suffer from minimally 
painful symptoms, the Centers for Disease Control and Prevention reports that UTIs are 
responsible for 13,000 deaths annually.3 About 50% of women will experience a UTI at 
some point in life, while 25% will experience a second, recurrent UTI within 6 months 
after treatment of the initial UTI.4 
Uropathogenic Escherichia coli (UPEC) cause nearly 90% of all diagnosed UTIs.5 
UPEC forms biofilm-like intracellular bacterial communities (IBC) after invasion of 
superficial facet cells in the bladder. This niche permits bacteria to reside and replicate 
in intracellular environments that are predominantly protected from host innate 
immunity and antibiotic treatments. UPEC can spread from IBCs to infect other urethral 
epithelial cells. This process is proposed to allow UPEC to develop quiescent 
intracellular reservoirs (QIRs)6 in the bladder tissue, resulting in bacteria reservoirs that 
remain viable for months within the bladder tissue despite the absence of bacteria in the 
urine.7,8 Multiple studies have used in vitro and in vivo9 models for UTIs to verify that 
UPEC can invade bladder epithelial cells10,11,12 and kidney epithelial cells.13  
Previous data supports that cranberry (Vaccinium macrocarpon) consumption may 




symptoms.14 The cranberry plant is an evergreen shrub that was first cultivated in North 
America. Cranberries are a major agricultural product in both the United States and 
Canada.15 Additionally, there is positive clinical evidence that cranberry products can 
be used prophylactically to reduce recurrent infections.16 Previous investigations of the 
responsible cranberry constituents have mainly focused on proanthocyanidins, 
particularly those with A-type linkages,17 and small organic acids.18  More recently, 
researchers have focused on the potential involvement of cranberry complex 
carbohydrates for beneficial effects against UPEC. 15,19 Our lab previously discovered 
that cranberry xyloglucan can interfere with biofilm formation by UPEC.20 More 
recently, we discovered that cranberry pectic oligosaccharides (cPOS) prevent 
quiescence in the UPEC strain CFT073.21  
In previous work,22 iridoid terpene glycosides were identified in fractions 
containing cPOS following chromatographic separations. The removal of iridoids is 
necessary to prove the activity of cPOS on UPEC in our biological assays. Our 
separation approach leveraged the differential solubility of the iridoids and cPOS in 
ethanol and water. HPLC and NMR spectroscopy were used to measure the residual 
impurities in the cPOS fraction, and the iridoid-free cPOS was then tested in a persister 
cell viability assay.  
Previously, we used NMR spectroscopy to determine that the structure of cPOS is 
comprised of repeating galacturonic acid units. However, the NMR approach was 
insufficient for differentiating between galacturonic and glucuronic acid 
monosaccharide units. In this thesis, we pursued a chemical derivatization approach to 




by a 1-phenyl-3-methyl-5-pyrazolone (PMP) reaction, and studied by HPLC in 
comparison to the appropriate standards. These experiments confirmed that cPOS is 
comprised of galacturonic acid monomers. 
Additional studies in this thesis were aimed at optimizing the separation of 
individual components of cPOS from a complex mixture. cPOS is a mixture of 
oligosaccharides with varying degrees of polymerization (DP). The effect of DP on the 
bioactivities of cPOS are currently unknown. The high polarity and water solubility of 
cPOS makes separation of its individual components challenging. We developed an 
HPLC method using HILIC chromatography to separate cPOS constituents of varying 
DPs. These studies may ultimately help resolve structure–activity relationships (SAR) 









REVIEW OF LITERATURE 
 
Oligosaccharides have been studied for their effects on various biological processes, 
including inhibition of bacterial translation and interruption of cell wall biosynthesis.23 
In addition, oligosaccharides are critical mediators of cancer, cellular recognition and 
microbial pathogenesis.24 Respectively, oligosaccharides may serve as potential 
treatments for various diseases, ranging from bacterial infections to type II diabetes.25 
While oligosaccharide natural products possess a wide spectrum of potential biological 
activities, they are relatively underrepresented in pharmacopeia.26 Generally, the 
chemical investigation of oligosaccharides is difficult as compared to other classes of 
molecules, such as linear peptides and oligonucleotides. The branched structures of 
oligosaccharides impede amplification methods like polymerase chain reaction (PCR). 
Therefore, procuring oligosaccharides by direct isolation from natural products is 
preferred,27,28 although this is complicated by their water-soluble nature. Sometimes, to 
maximize the activity of oligosaccharides, modification such as esterification and 
glycosylation would be performed.29 Also, these polar, functionalized oligosaccharides 
can be present at negligible concentrations, and thus are more challenging to detect, 
isolate and identify than other natural products.26 
One of the more well studied examples are human milk oligosaccharides (HMO).  
These sialylated oligosaccharides and glycans were first discovered as a prebiotic 




infants.  HMO promote the proliferation of beneficial bacteria by serving as a metabolic 
substrate.31 Sialylated human milk oligosaccharides enhance the newborn immature 
immune system and are crucial for the proper development and well-being of the gut.32 
Like other dietary oligosaccharides, cranberry oligosaccharides have shown 
various bioactivities, such as inhibition of bacterial adhesion,33 enhanced growth of 
commensal bacteria,34 and reduced biofilm formation.14,35 These soluble oligosaccharides 
make up to higher than 20% w/w in many cranberry materials.15 However, the 
contribution of oligosaccharides to the proposed health benefits of cranberry are largely 
unresolved.  
Since cranberry is well known for its contributions to urinary tract health, 
understanding the potential contributions of each constituent may aid in optimizing 
cranberry products. Oligosaccharides may play a role in UTI prevention since these may 
be found in the urine. Coleman et al. demonstrated that an octasaccharide 
arabinoxyloglucan, a water soluble type of hemicellulose oligosaccharide isolated from 
cranberry, could be isolated from the urine of swine that were fed a cranberry product.19 
Moreover, this molecule demonstrated antiadhesion properties against bacteria. This 
suggests that dietary oligosaccharides may be similarly excreted into human urine. 
Pectic oligosaccharides (POS) are the hydrolysis products of pectin. Pectins are 
high molecular weight (MW) structural polysaccharides found inside the lamella of 
primary cell walls within almost all higher plant tissues.37 Pectin is a complex of acidic 
polymers which is comprised of homogalacturonic and branched rhamnogalacturonic 
regions. These pectins are broken down by natural enzymes during fruit ripening and 




of polymerization (DP).38 Pectin is abundant in whole fresh cranberries, and with the 
addition of heat and sugar during the juice making process, pectins can induce gel 
formation in the juice.39 Therefore, commercial cranberry juice is treated with pectinase 
macerations before filtering to increase juice yields.40 This suggests the inclusion of 
significant pectic oligosaccharides in consumer cranberry products such as juice.  
POS can be produced from agricultural byproducts, further enhancing the potential 
for developing biomedicines and/or functional foods. For instance, the low-calorie and 
odorless POS can be used in anti-obesity diets41 and the non-digestible property enables 
POS to selectively affect bacteria flora in the colon.42 Notably, pectic oligosaccharides 
also have immunomodulatory and anti-inflammatory43,44 activity. POS possess 
antioxidant activity45 and are reported to provide potential protection against 
cardiovascular diseases.46 Individual cPOS molecules from cranberry are generated from 
cranberry pectin by various treatment methods, such as enzymatic,47 chemical48 and 
physical41 methods. Among them, enzymatic treatment for POS degradation is 
considered as the most common due to the minimum chemical modifications as 
compared to other pretreatment methods.49 It has been reported that endo-
polygalacturonase can randomly cleave the glycosidic bond of the α-(1–4)-
polygalacturonan in pectin.49 Also, pectin methyl esterase and pectin acetyl esterase can 
remove methyl esters and acetyl groups on galacturonic acid residues.50 
As mentioned previously, the pectinase enzyme mixtures are used to degrade cell 
wall structures biochemically to increase juice production. Pectinase includes pectin 
lyase and pectate lyase, both of which are able to cleave the smooth region of pectin, a 




residues containing a 4,5-unsaturated galacturonic acid methyl ester at the non-reducing 
end.51 De-esterified products treated with of Klerzyme 150 pectinase, a pectinase enzyme 
mixture, resulted in unsaturated oligosaccharides after heat treatment.52 Interestingly, our 
group previously isolated unsaturated methyl-esterified galacturonic acid from a 
cranberry fraction that had been treated with same pectinase.21 
Further research is required to understand the possible roles and uses of cPOS in 
UTI prevention. While cPOS has been shown to inhibit UPEC from residing in a 
quiescent state,53 the impact of oligosaccharide degree of polymerization is unknown.  
Furthermore, studies of cPOS on UPEC persister cells have been hindered by impurities 
that remain following various chromatographic separations.  Also, the monosaccharide 
composition of cPOS has yet to be proven using chemical derivatization methods. The 
research presented in this thesis helps overcome these current limitations in our 












1D and 2D NMR (HSQC) experiments were collected on an Agilent NMR 500 
MHz spectrometer (Varian VNMRS 500MHz, Agilent Technologies) in D2O (99.99%, 
Sigma-Aldrich) at 25 °C. LC/MS analysis was performed on a Shimadzu Prominence 
UFLC system coupled to an AB Sciex QTRAP 4500 mass spectrometer with 
electrospray ionization source in the negative ion mode. Flash chromatography used a 
Combiflash Rf200 equipped with a 100 g C18 RediSepRf High Performance Gold 
column (Teledyne ISCO). Semi-preparative HPLC experiments were performed on a 
Shimadzu Prominence i-series HPLC, using TSKgel Amide-80, 7.8 mm I.D x 30 cm, 
10 µm column. Analytical HPLC experiments were also performed on the Shimadzu 
Prominence i-series HPLC using a 4.6 × 250 mm, 5 µm TSKgel Amide-80 HR HILIC 
column. Centrifugation was conducted with an Eppendorf 5804 centrifuge. All solvents 
used were HPLC grade and purchased from Sigma-Aldrich Chemical Co. (St. Louis, 
MO, USA). 
 
3.2 Fractionation of cranberry (V. macrocarpon) materials  
A pectinase (Klerzyme 150, DSM Food Specialties, IN) degraded cranberry hull 
extract (1.0 g) was dissolved in 20 mL distilled water and fractionated by reversed phase 
flash chromatography. After purging and pre-conditioning a Combi-Flash 




Gold) was loaded with the cranberry hull extract sample and sequentially eluted with 
500 mL of distilled H2O (Fraction Cranf1W, 752 mg, 37.6%), 500 mL of 15% 
methanol/water (Fraction Cranf1b, 480 mg, 24.0%), and finally 500 mL of MeOH 
(Fraction Cranf1M, 564 mg, 28.2%) at 35 mL/min. The three fractions were 
concentrated by rotary evaporation and lyophilization and stored at -20 °C. 
 
3.3 Trituration of active fractions 
Trituration of fraction Cranf1b to remove iridoid terpenes was accomplished by 
sonicating 200 mg Cranf1b in 30 mL 95% ethanol/water and then centrifuging the solids 
at 17,000 x g for 8 min. The collected solids were then dissolved in deionized (DI) H2O 
and lyophilized. The trituration step was repeated twice prior to further separation by 
PGC chromatography to provide sample cPOS-t (91.7%, w/w dry). 1H NMR data and 
analytical HPLC analysis of the resulting products were assessed to determine the 
iridoid terpenes were successfully removed by trituration. HPLC was accomplished on 
a Prominence i-series system (Shimadzu) using a TSKgel Amide-80 HR HILIC column 
(4.6 × 250 mm, 5 µm, TOSOH Bioscience, Tokyo, Japan) with a 1.0 mL/min flow rate 
and 35 °C while monitoring at UV 235 nm (20 µL injections of a 10 mg/mL sample). 
The column was first eluted with 80% ACN/water (+0.1% formic acid) for 2 min, 
followed by a linear gradient to 40% ACN/water (+0.1% formic acid) for 20 min and 
then held for 5 min.  
 




Cranf1b was further fractionated using porous graphitized carbon (PGC) 
chromatography (1 g cartridges, ThermoFisher Scientific). The PGC cartridge was first 
eluted with 50% ACN/water for cleaning and then equilibrated with distilled water for 
conditioning. A total of 40 mg of Cranf1b was dissolved in 2 mL distilled water, loaded 
onto the PGC cartridge, and eluted sequentially with 18 mL H2O, 12 mL 10% 
ACN/water (+0.1% TFA), and 18 mL 30% ACN/water (+0.1% TFA). All fractions were 
lyophilized and stored at -20 °C. 
 
3.5 Structure determination of cPOS 
All the individually collected fractions from step 3.3 were analyzed by LC/MS and 
1D and 2D NMR spectroscopy for structure determination. The LC/MS analyses were 
performed on an Amide-80 column using the HPLC conditions described above. 
LC/MS were operated in negative ion mode and while scanning in a range from m/z 200 
to m/z 2000. For NMR analysis, samples were deuterium exchanged twice by dissolving 
in D2O (99.99%, Sigma-Aldrich) and shaking for 5 min. 1H and HSQC NMR 
experiments were conducted on a 500 MHz NMR spectrometer at 25 °C, with 
compounds dissolved at 10 mg/mL. 1H NMR spectra were acquired with 16 scans. 
HSQC spectra were obtained with 4 scans per increment and 128 t1 increments. 
 
3.6 Determination of monosaccharides composition by PMP-derivatization 
The composition of the poly-galacturonic acid backbone of cPOS was determined 
by acid hydrolysis of cPOS followed by derivatization with 1-phenyl-3-methyl-5-




follows.54,55 10 mg cPOS was hydrolyzed in 1 mL of 2 M TFA at 90 °C for 5 h. After 
cooling to room temperature, the reaction mixture was centrifuged at 3000 rpm for 5 min. 
The supernatant was evaporated in vacuo to remove residual TFA. The hydrolysate 
mixture was dissolved in 1 mL distilled water and treated with 30 µL NaOH (0.3 M) and 
20 µL PMP solution (0.5 M in methanol) for derivatization. The mixture was incubated 
at 70 °C for 60 min, cooled to room temperature and neutralized with 30 µL of HCl 
(0.3 M). The mixture was then extracted with 1 mL chloroform. The aqueous layer was 
filtered by passing through a 0.45 µm syringe filter. Glucuronic acid (2.0 mM), 
galacturonic acid (2.0 mM) and a distilled water blank were subjected to the identical 
reaction conditions. HPLC analyses of PMP-labeled samples were conducted on a 
Prominence i-series system (Shimadzu) using a BAKERBOND C18 column 
(4.6 mm × 250 mm, 5 𝜇m, J.T. Baker Inc., Phillipsburg, NJ, USA). The injection volume 
was 20 µL with a flow rate of 1.0 mL/min at 35 °C. Mobile phase A was 10% 
ACN/water with 0.045% KH2PO4–0.05% triethylamine buffer (pH 7.5) and mobile 
phase B was 100% ACN. The column was eluted with 6% B for 4 min, a gradient of 6–
12% B for 1 min and then 12% B for 20 min. The UV detection wavelength was 254 nm. 
 
3.7 Purification of oligosaccharides with various degrees of polymerization 
Oligosaccharides with different DPs in 10% PGC fraction were sequentially 
purified by HPLC using a TOSOH Tskgel Amide-80 HR column (7.8 mm I.D x 30 cm, 
10 µm) (TOSOH Bioscience) with a 1.6 mL/min flow rate and 35 °C while monitoring 
at UV 235 nm (100 µL injections of a 20 mg/mL sample). The column was initially 




gradient to 40% ACN/water (+0.1% formic acid) for 20 min and then held for 5 min. 
Fractions corresponding to cPOS with different DPs were collected based on UV 
absorbances and/or retention time and concentrated by lyophilization. 
 
3.8 Persister cell viability assay and quiescence lawn assay 
The persister cell viability assay was performed following a previously published 
protocol.6 Briefly, E. coli strain CFT073 was streaked from cryo-stocks onto LB agar 
plates and incubated overnight at 37 °C. A loopful of cells from the plate were added to 
10 mL 0.4% glucose M9 minimal media in a 125 mL culture flask and incubated 
overnight at 37 °C and 200 rpm. Cultures were diluted in fresh 0.2% glucose M9 
minimal media to an optical density (OD600) of 0.1 (~108 CFU/mL) and grown in the 
presence of ampicillin sodium (0.1 mg/mL) to generate persister cell fractions. The 
cultures were incubated shaking (200 rpm) at 37 °C and viable counts were measured 
at 0 h, 4 h, and 24 h by plating on LB media. Test cultures were treated with cPOS 
fractions at 1-2 mg/mL. Control experiments included cultures without antibiotic (cPOS 
only) and cultures without antibiotic or cPOS. 
The quiescence lawn assay also followed a published protocol.6 Briefly, overnight 
cultures of CFT073 were prepared in 0.4% glucose M9 minimal media as described 
above for the persister cell viability assay. Bacteria from this culture were diluted to a 
final concentration of 105 CFU in 4 mL of liquid overlay media (0.2% glucose M9 
minimal media with 0.9% noble agar at 45 °C). Each 4 mL overlay inoculum was poured 
over a prewarmed (37 °C) 0.2% glucose M9 minimal media agar plate immediately after 




ajar. Test solutions were added to the overlay media and allowed to dry before 
incubating the plate upside down at 37 °C for 24 h or 48 h. No growth of E. coli in the 
overlay is considered to be quiescent if it is able to be reversed with the positive control 








4.1 Separation of iridoid terpene glycosides from cPOS 
In previous work, three iridoid terpene glucosides (Figure 1) were identified as 6,7-
dihydromonotropein (a), monotropein (b) and deacetylasperulsidic acid (c) in fractions 
containing cPOS following chromatographic separations. Iridoids were separated and 
analyzed by ESI-TOF-MS in the negative ion mode (Figure 2). The major peak showed 
two ions in negative mode at m/z 391.1204 and 389.1050, suggesting two co-eluted 
molecules which were subsequently further separated by C18 column chromatography 
as a and b, respectively. The second peak showed one negative ion at m/z 389.1050 (c).  
Although these iridoid glucosides were minor impurities and inactive in the in vitro 
quiescence inhibition assay (data not shown), the removal of iridoids was necessary to 
prove the activity of cPOS on UPEC in our persister cell assay.  
The separation approach described here was based on the differential solubility of 
the iridoids and cPOS in ethanol and water. We found that these impurities could be 
removed from the cPOS fraction by exploiting their differential solubility in ethanol. 
Cranf1b was triturated with 95% aqueous ethanol prior to PGC separation, producing a 
cPOS fraction devoid of iridoid glycosides (cPOS-t, 91.7%, w/w dry) as determined by 
HPLC analysis (Figure 3) and 1H NMR analysis (Figure 4). 10 mg/mL solutions of 
cPOS fraction and iridoid-deficient cPOS fraction (cPOS-t) were analyzed by HILIC 
HPLC using UV-monitoring (235 nm). Figure 2 shows a comparison of pre- and post-




Moreover, the absence of typical 1H NMR signals corresponding to the double bonds 
on the cyclopentanopyran scaffold of iridoid glucosides in cPOS-t further supports the 
successful removal or iridoid terpenes from cPOS by the trituration method (Figure 4). 
HSQC NMR analysis of the cPOS-t cranberry fraction revealed proton and carbon 
resonances with chemical shifts characteristic for poly-uronic acids. Additional 
structural features included a methoxy group at δH 3.70/ δC 52.8 and a vinylic methine 
at δH 6.00/ δC 111.8 (Figure 5). UV absorption maxima at 235 nm was consistent with 
the presence of an α, β-unsaturated carboxylic acid.  
The cPOS-t fraction was tested in a persister cell viability assay and found to 
maintain activity similar to cPOS (Figure 6,7). Treatment of E. coli CFT073 with both 
cPOS and ampicillin resulted in >1000-fold fewer persister cells versus treatment with 
ampicillin alone.20 A similar reduction of persister cells was obtained when conducting 
the assay with cPOS-t (Figure 6). The viable cell counts in the E. coli CFT073 cultures 
decreased slightly during the first 4 h of incubation in both the presence and absence of 
ampicillin. By 24 h, E. coli CFT073 had grown to just over 109 CFU/mL in the absence 
of ampicillin. In contrast, the presence of ampicillin reduced the viable counts an 
additional ~1000-fold over the next 20 h, to about 106 CFU/mL. As shown by the results 
in Figure 5, in the presence of 1 mg/mL cPOS and absence of ampicillin, E. coli CFT073 
viable counts increased rapidly, reaching stationary phase within 4 h. Importantly, in 
the presence of both the cPOS and ampicillin, E. coli CFT073 viable counts decreased 







Figure 1. Structures of iridoid glucosides: 6,7-dihydromonotropein (a), and 
deacetylasperulsidic acid (b) and monotropein (c). 
 
Figure 2. LC-MS analysis in the negative ion mode of iridoid glucosides showing 










































Figure 3. HILIC HPLC chromatogram of cPOS (Top) and cPOS-t (Bottom) at 235 nm. 
6,7-dihydromonotropein (a), deacetylasperulsidic acid (b) and monotropein (c). Only 





Figure 4. 1H NMR spectrum (D2O, 500 MHz) of standards (purified 4-mer pectic 
oligosaccharide and iridoids), and cPOS-t (triturated 10% PGC). The 1H NMR analysis 
indicated the triturated 10% PGC was similar to 4-mer pectic oligosaccharide and 










Figure 5. HSQC spectrum of cPOS-t (D
2
O, 500 MHz). The 1H and HSQC NMR spectra 
of the active cranberry fraction revealed proton and carbon resonances with chemical 
shifts characteristic for poly-uronic acids. 
 
Figure 6. Persister cell viability treating with cPOS-t (CFT073+ampicillin+ cPOS-t) is 
significantly different at 4 h (**- P ≤ 0.01) and 24 h (**-P ≤ 0.01), in comparison to 
CFT073+ampicillin. CFT073 cell viability with (CFT073+cPOS-t) or without cPOS-t 
treatment (CFT073) were evaluated as controls.  cPOS-t: 2 mg/mL; ampicillin: 0.1 





Figure 7. Persister cell viability treating with cPOS (CFT073+ampicillin+ cPOS) is 
significantly different at 4 h (**- P ≤ 0.01) and 24 h (***-P ≤ 0.01), in comparison to 
CFT073+ampicillin. CFT073 cell viability with (CFT073+cPOS) or without cPOS 
treatment (CFT073) were evaluated as controls.  cPOS: 2 mg/mL; ampicillin: 0.1 
mg/mL. Adapted from Sun et al.21  
 
4.2 Verification of the cPOS monosaccharide composition by chemical 
derivatization 
Previously, our lab used NMR spectroscopy to determine the structure of cPOS is 
comprised of repeating galacturonic acid units.22 However, the NMR approach is 
limited in its ability to differentiate between galacturonic and glucuronic acid 
monosaccharide units, since the two anomeric proton peaks generally used to 
differentiate between different monosaccharide residues are very similar in the case of 
these two sugars. Therefore, a chemical derivatization approach was applied to 
complement the previous NMR studies. Specifically, cPOS was hydrolyzed, modified 
by a 1-phenyl-3-methyl-5-pyrazolone (PMP) reaction, and analyzed by reversed-phase 




HPLC traces, the monosaccharide composition of cPOS was determined to be 
comprised of galacturonic acid units. Figures 8B and 8C show the retention times for 
PMP reaction products with glucuronic acid and galacturonic acid, respectively. 
Comparison of retention time between cPOS hydrolyzed products (Figure 8D, tR= 6.0 
min) and standard derivatives (PMP, tR = 3.3 min; glucuronic acid, tR = 4.6 min; 
galacturonic acid, tR = 6.0 min) confirms that the cranberry POS oligosaccharides were 






Figure 8. Uronic acid identification of cPOS. cPOS, glucuronic acid and galacturonic 
acid were derivitized with PMP and analyzed by HPLC as described in the Methods. 
The stacked chromatograms show the results for reactions conducted with PMP without 
an added carbohydrate (A); Glucuronic acid (B); Galacturonic acid (C); and cPOS 
hydrolysate (D). The peak with a retention time at 6.0 min in D indicates that cPOS is 
comprised of galacturonic acid. Adapted from Sun et al.21  
4.3 Purification of cPOS for determining the effect of DP on UPEC phenotypes 
With the active cPOS monosaccharide composition verified, we next sought to 
enable structure-activity relationships (SAR) of cPOS components with respect to the 
observed reversal of CFT073 quiescence. It is well recognized that DP is one of the 
crucial factors with regard to the bioactivities of oligosaccharides.15,27 To assess the 
effect of cPOS DP on reversal of CFT073 quiescence, a separation method was 
developed for isolation of cPOS components with different DPs. Good separation was 
ultimately achieved using hydrophilic interaction chromatography (HILIC) with 
hydrophilic (amide) stationary phases and reversed-phase type eluents. In a HILIC 
system, the surface forms a water-rich layer on the polar stationary phase, leaving a 
water-deficient mobile phase, forming a liquid/liquid extraction system. The analytes 
interact between these two layers. Compounds with higher polarity will elute later since 
they have higher interaction with the stationary aqueous layer. As for oligosaccharides, 
the oligomers with higher DPs have relatively higher polarity, which elute later while 
oligomers with lower DPs elute earlier.  
Taking previous analytical HILIC HPLC separation results into consideration,56 a 




system comprised of acetonitrile and water with 0.1% TFA was the best mobile phase 
for cPOS separation. The presence of TFA in eluting solvents increased the acidity 
which resulted in a better separation for acidic compounds. In our case, since the 
molecules of interest consisted of galacturonic acid oligomers, ensuring the molecules 
were fully protonated was expected to give better separation, as well as increase the 
consistency of each separation batch (Figure 9). A 1.5 mL/min flowrate with a semi-
preparative HILIC column provided chromatographic separation similar to using the 
analytical column at 1.0 mL/min (Figure 9). 
 
Figure 9. Analytical HILIC HPLC chromatography of cPOS by using TOSOH Tskgel 
Amide-80 HR column (7.8 mm I.D x 30 cm, 10 µm), 1.0 mL/min. 
 
The collection of cPOS components from the semipreparative separation was based 
on the chromatographic peaks. Considering the non-polar impurities observed 
previously, fractions were collected starting from fraction 1 (tR= 15 min) to fraction 10 
(tR= 27 min) for bioassay analysis (Figure 10). All the combined eluents prior to 14.7 
min were combined as fraction 0. By injecting 40 mg of cPOS-t, a total of 11 fractions 





Figure 10. Preparative HILIC HPLC chromatography of cPOS by using TOSOH 
Tskgel Amide-80 HR column (7.8 mm I.D x 30 cm, 10 µm), 1.5mL/min. For each 40 
mg of cPOS-t, the certain amount of fractions 0−10 were obtained (fraction 0: 4.7 mg, 
fraction 1: 1.4 mg, fraction 2: 1.6 mg, fraction 3: 1.0 mg, fraction 4: 1.6 mg, fraction 5: 
1.7 mg, fraction 6: 2.9 mg, fraction 7: 1.9 mg, fraction 8: 3.0 mg, fraction 9: 3.5 mg and 
fraction 10: 3.8 mg). 
 





















The semipreparative HILIC HPLC not only gave a good separation of impurities 
and cPOS, but also separation of cPOS with different DPs. As shown in Figure 10, the 
analysis of 1H NMR spectra of all 11 fractions indicated that fractions 0−2 were 
impurities with only trace amounts of oligosaccharides while fractions 3−10 showed 
resonances consistent with cPOS.  This includes the typical proton signals of a vinylic 
methine around δH 6.10 and methoxy group around δH 3.70. The successful separation 
method using HILIC HPLC set the stage for preliminary structure–activity relationship 
(SAR) analysis. According to the activity result (Figure 12), the activity variation of 
each fraction suggested that the DPs of cPOS plays a role in reversing UPEC quiescence. 
Only fraction 4 showed activity (5 µL spot; 10 mg/mL) while no obvious positive effects 
of other obtained fractions were observed, indicating that only cPOS with a specific and 
relatively low DP might be responsible for the observed activity. Further 
characterization of the active fraction and comparison to the inactive ones will provide 







Figure 12. CFT073 quiescence assay using glucose-free M9 plates. A colony of 
actively growing CFT073 toothpicked into the agar plate as positive control; Sample 
A:  cPOS-t, (10 mg/mL); Sample B: Cranf1b, (10 mg/mL); Fractions 1 to 10 were 








Polysaccharides exhibit a variety of biological functions and characterizing their 
monosaccharide composition is a critical first step to understanding their structure and 
function. Previously, our lab used 1H and HSQC NMR spectroscopy to deduce the 
structure of cPOS, revealing chemical shifts for the active cranberry fraction consistent 
with polyuronic acids. In this study, chemical derivatization was used to confirm that 
cPOS is comprised of galacturonic acid residues. The smooth region of pectin is called 
galacturonans which are linear chains of α-(1–4)-linked D-galacturonic acid. Hence, 
cPOS is hypothesized to be the hydrolysis product of pectin. 
Acid hydrolysis of cPOS followed by PMP derivatization required optimization. 
Temperature and pH value are two crucial parameters for both the hydrolysis and 
derivatization reactions. Galacturonic acid oligosaccharides are relatively more stable 
than other saccharides.50 However, higher reaction temperatures will lead to degradation 
of oligosaccharides. We used a moderate temperature (90 ℃ versus 120 ℃) and longer 
reaction time (5 hours compare to 2 hours)57 to successfully hydrolyze our product. 
During the derivatization step, carbanions are required to form a Schiff base and 
subsequent reactions to generate derivatives, which means the reaction should be 
conducted under basic conditions. Since uronic acids are more acidic than other sugars 
due to their carboxylic acid, the addition of NaOH was necessary to adjust the pH and 




Three minor impurities, all iridoid glucosides, were previously identified by our 
lab in the active 10% cPOS fraction obtained using porous graphitized carbon 
chromatography. Specifically, these were identified as 6,7-dihydromonotropein, 
deacetylasperulsidic acid and monotropein and found to be inactive in the quiescence 
assay. Previous studies have shown that the iridoid glucosides monotropein and 6,7-
dihydromonotropein also lack antiadhesive effects against Escherichia coli.58,59 We 
sought to remove these impurities to provide a more highly purified cranberry pectic 
oligosaccharide sample for biological study. Based on the differential solubility in 
ethanol of iridoid glucosides and cPOS, iterative trituration with 95% aqueous ethanol 
proved successful for removing the iridoid impurities before PGC fractionation. HPLC 
and 1H NMR analyses verified the removal of iridoid glucosides, and the persister cell 
bioassay again confirmed that these were not responsible for the bioactivity of cPOS.  
Degree of polymerization is another crucial factor to be determined when 
characterizing the activity of cPOS against UPEC. Due to the limitation of column size, 
our group previously only separated small quantities and determined the structures of 
two pectic oligosaccharides, namely uG3m2 and UG4m3.21 In this thesis work, a semi-
preparative HPLC method using HILIC chromatography was developed for the 
purification of cPOS components with variable DPs. 1H NMR results further confirmed 
that cPOS with variable DPs could be separated from the complex mixture of 
oligosaccharides.  This method will be useful for future efforts to further investigate the 





Anti-inflammatory effects of cPOS 
1. Introduction 
Cranberry is the fruit of the evergreen shrub Vaccinium macrocarpon and has been 
extensively studied for benefits to human health, including urinary tract health15 and 
anti-inflammation effects.60,61 Inflammation is an important process for protecting 
against infections and healing wounds. However, inflammation is also implicated in 
numerous chronic diseases, including cancer.62 Dietary sources of anti-inflammatory 
compounds could therefore provide beneficial health outcomes. In previous 
investigations of the anti-inflammatory properties of cranberry constituents, 
investigators have focused on proanthocyanidins,63 especially A-type 
proanthocyanidins,64 neglecting the potential contributions of cranberry oligosaccharide 
constituents. 
Yet, polysaccharides from botanical sources have previously shown various effects 
on inflammation pathways. Some polysaccharides have been shown to increase the 
expression of cytokines and chemokines, including tumor necrosis factor (TNF-α), 
Interleukin-1β (IL-1β)65 and IL-6.66 On the contrary, some citrus pectins can exert anti-
inflammatory action. Also, bupleurum polysaccharides were found to up-regulate 
phagocytic activities67 and inhibit secretion of inflammation related cytokines.68 This 
multi-function can be referred as biological response modifiers (BRMs). Previously, our 
lab found xyloglucan and pectic oligosaccharides in cranberry extract subfraction 




and activate macrophages.65 However, how the effect of xyloglucans and pectic 
oligosaccharides on the secretion of cytokines is unknown.  
In this study, we tested the effects of cranberry extracts enriched in 
oligosaccharides for modulation of the pro-inflammatory cytokines TNF-α, IL-1β, and 
IL-6. An attempt to identify the active components was pursued using bioactivity guided 
isolation. 
2. Anti-inflammatory evaluation of oligosaccharide-rich cranberry extracts by 
measuring TNF-α and IL-1β secretion by THP-1 cells 
To evaluate the anti-inflammatory properties of cranberry extract, a model was 
applied initially to examine effects against TNF-α and IL-1β. THP-1 cells were seeded 
at a density of 5*104 cells per well in 48 well plate. PMA (25 ng/ml) was added to induce 
differentiation for 48 hours. Next, the PMA was removed and cells were incubated with 
PMA free medium for another 24 hours. LPS was added for 4 hours, then samples were 
added and incubated for another 1 hour. Nigericin was then added for another 1 hour. 
The supernatant was collected and IL-1β and TNF-α were measured by ELISA. 
Nigericin is an inducer for inflammasome activation and boosts IL-1β secretion. 
Inflammasome activation needs two inducers: LPS and nigericin. MCC is a positive 
control small molecule that specifically inhibits inflammasome activation. Fraction 
Cranf1b its PGC subfractions (Scheme 1) were tested and showed positive results for 
the anti-inflammatory activity by IL-1β and TNF-α assays (Figure 13). 
LPS stimulated the release of TNF-α (114.87 ± 5.98 pg/mL) and IL-1β (303.30 ± 




pg/mL and 135.37 ± 26.39pg/mL, respectively). LPS and nigericin treatment also 
resulted in elevated TNF-α (53.59 ± 9.68 pg/mL) and IL-1β (583.35 ± 72.52 pg/mL) 
concentrations. Fraction S2 (70% water/30% ACN portion) at a concentration of 0.01 
µg/mL was the most effective at reducing the secretion of TNF-α by 67% (37.97 ± 3.92 
pg/mL), while none of the samples demonstrated a reduction in IL-1β secretion.  
 
 
Scheme 1. Sample preparation for TNF-α and IL-1β assay. Sample preparation method 
was detailed in Sections 3.2 and Section 3.4 of this thesis. Fraction S1: Cranf1b portion 
and fraction S2: 70% water/30% ACN portion, highlighted in red, were determined to 








































































































Figure 13. Results of IL-1β and TNF-α assay for fractions obtained from sample 
preparation of cranberry juice extract powder. Fraction S1: Cranf1b portion; fraction S2: 
70% water/30% ACN portion; fraction S3: 90% water/10% ACN portion; fraction S4: 
100% water portion. Data shown as mean ± SE. 
 
3. Anti-inflammatory evaluation of cranberry extracts for modulating TNF-α and 
IL-6 secretion 
The previous experiments suggested that fraction S2 showed the most promise for 
impacting pro-inflammatory cytokine production.  This fraction had been generated 
using porous graphitized carbon chromatography PGC 30% ACN fraction (Scheme 2). 
To further separate this active fraction, an HPLC method was devised to for the 
separation of oligosaccharides. The conditions were as follows: UV detector was set at 
254 nm (Figure 14, pink trace), flow rate 1.5 mL/min. The TSKgel Amide-80 column 
(10 µm, 7.8 mm I.D x 30 cm) was initially eluted with 60% ACN/water (+0.1% formic 
acid) for 2 min, followed by a linear gradient to 40% ACN/water (+0.1% formic acid) 












































































































Similar to the previously described method, the anti-inflammation effects of HPLC 
separation fractions from active fraction (70% water/30% ACN portion) was tested 
using assays that measure IL-6 and TNF-α. THP-1 cells were seeded into 48 well plates 
at a density of 50,000 cells/well in medium with PMA (25 nM) for 48 hours. Following 
this period, cells were visually checked for adherence and proper morphology before 
exchanging differentiation medium to serum free medium for 24 hours prior to sample 
treatment. Test samples were weighed and dissolved in FBS free medium before being 
diluted in cell culture medium at concentrations of 100 and 10 µg/mL. CE at these 
concentrations were added to each respective set of wells for 1 hour before being 
exposed to LPS at 1 µg/mL for 24 hours. Following LPS exposure, medium was 
collected, centrifuged and assayed for IL-6 and TNF-α using respective ELISA kits. 
LPS was able to stimulate the release of TNF-α (289.56 ± 25.97 pg/mL) and IL-6 
(753.32 ± 12.33 pg/mL) into culture media whereas the blank control did not produce 
significant levels (30.51 ± 2.16 pg/mL and 278.51 ± 36.42 pg/mL respectively). Fraction 
S4 (first subfraction obtained from 70% water/30% ACN portion) at a concentration of 
100 µg/mL was the most effective at reducing the secretion of TNF-α by 94% (17.13 ± 
3.88 pg/mL) and at 100 µg/mL, IL-6 secretion was significantly attenuated by 





Scheme 2. Further separation of active fraction (70% water/30% ACN portion). All 
subfractions were tested for TNF-α and IL-6 assay. The active subfraction (S4) was 
highlighted in red. 
 
 
Figure 14. HPLC separation of the active S3 fraction (70% water/30% ACN portion). 
A total of four subfractions (S4−S7) were obtained by HPLC separation. Fractions were 
collected based on retention time (fraction S4: 2.0 min−7.0 min; fraction S5: 7.0 







Figure 15. Results of IL-6 and TNF-α assays for fractions obtained from sample 
preparation of cranberry juice extract powder. Fraction S1: Cranf1b portion; fraction S2: 
Cranf1M; fraction S3: 70%water/30% ACN portion; S4−S7: four subfractions obtained 
from HPLC separation of S3; S8: iridoid-rich fraction. Data shown as mean ± SE.  
 
4. Anti-inflammatory evaluation of subfractions of cranberry extract in THP-1 
monocytes 
To further evaluate the anti-inflammatory properties of Cranberry Extract, LPS 
sensitive, phorbol 12-myristate 13-acetate (PMA) differentiated THP-1 monocytes were 
used. THP-1 monocytes were differentiated to macrophages according to previously 

































































































































































































































































density of approximately 200,000 cells/mL and allowed to incubate for at least 24 hours 
prior to PMA exposure. PMA was then added directly to each well at final concentration 
of 25 nM for 48 hours. Following this period, cells were visually checked for adherence 
and proper morphology before exchanging existing differentiation media to serum free 
media for at least 24 hours prior to compound treatment. 
Cranberry Extract (CE) was initially weighed and dissolved in PBS before being 
diluted in cell culture medium at concentrations of 100 and 0.01 µg/mL. CE at these 
concentrations were added to each respective set of wells for 1 hour before being 
exposed to LPS at 1 µg/mL for 6 hours. Following LPS exposure, media was collected, 
centrifuged and assayed for IL-6 and TNF-α using respective ELISA kits (Biolegend, 
San Diego CA USA). We observed that LPS is able to stimulate the release of TNF-α 
(1027 ± 27.4 pg/mL) and IL-6 (229.6 ± 12.69 pg/mL) into culture media whereas the 
vehicle control did not produce significant levels (50.75 ± 0.05 pg/mL and 11.67 ± 0.18 
pg/mL respectively). Resveratrol (RESV) was used at 20 µM and was found to decrease 
concentrations of both TNF-α (944.8 ± 25.7 pg/mL) and IL-6 (44.3 ± 4.63 pg/mL).  CE 
at a concentrations of 0.01 µg/mL was the most effective at reducing the secretion of 
TNF-α by 32% (694.7 ± 88.16 pg/mL) and at 0.1 µg/mL, IL-6 secretion was 





Figure 16. Cranberry extract significantly attenuates the release of pro-inflammatory 
TNF-α and IL-6 cytokines. Differentiated THP-1 Cells were pre-treated with vehicle 
(DMSO), RESV (20 µM), or CE (100 to 0.01 µg/mL) for 1 hour before being exposed 
to LPS (1 µg/mL) for 6 hours.  Media was then collected and saved for cytokine analysis 
with respective ELISAs.  Data shown as mean ± SE. All comparisons made to LPS p < 
0.05 * , p < 0.01 ** , p <0.001 ***, p<0.0001 ****. 
 
To model the systemic exposure of dietary oligosaccharides from cranberry, THP-
1 monocytes, an immortalized human cell line was exploited for its ability to react to 
various endogenous and exogenous stimuli. Moreover, these cells have been optimally 
differentiated to macrophages effectively increasing their sensitivity to these stimuli. 
Lipopolysaccharide is typically used to elicit an immune response by engaging TLR4 
pathway further causing a release of pro-inflammatory/pro-oxidant signaling molecules. 





The cytokines measured only represent a small portion of other possible signaling 
molecules that interact with other monocytes, adipocytes and dendritic cells and other 
surrounding tissues. More work is needed to construct a signaling network of cytokines 
and chemokines. Gene expression data of these inflammation-based molecules has 
already been explored by another group71 using a similar treatment methodology; 
however, the composition of their extract is markedly different to this oligosaccharide 
and terpenoid enriched fraction. Moreover, these macrophages respond to molecular 
patterns from pathogen and damaged cells therefore, it is not unlikely that these 
oligosaccharides may prevent the interaction of LPS or truly act upon a transcription 
factor or protein target(s) within the cell. Further experiments are also warranted to 
ascertain the extent of permeability and confirm which major constituents are 
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